Literature DB >> 18515658

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.

Sanjai Sharma1, Alan Lichtenstein.   

Abstract

The mechanism by which the glucocorticoid (GC) dexamethasone induces apoptosis in multiple myeloma (MM) cells is unknown, although previous work suggests that either transactivation through the glucocorticoid response element (GRE), transrepression of NF-kappaB, phosphorylation of RAFTK (Pyk2), or induction of Bim is important. We studied this question by ectopically expressing mutant glucocorticoid receptors (GRs) in the dexamethasone-resistant MM1R cell line, which has lost its GR. Lentiviral-mediated reexpression of wild-type GR restored GRE transactivation, NF-kappaB transrepression, RAFTK phosphorylation, Bim induction, and dexamethasone-induced apoptosis. We then reexpressed 4 GR mutants, each possessing various molecular effects, into MM1R cells. A perfect correlation was present between induction of GRE transactivation and induction of apoptosis. In contrast, NF-kappaB transrepression and RAFTK phosphorylation were not required for apoptosis. Although not required for dexamethasone-mediated apoptosis, NF-kappaB inhibition achieved by gene transfer suggested that NF-kappaB transrepression could contribute to apoptosis in dexamethasone-treated cells. Dexamethasone treatment of MM1R cells expressing a mutant incapable of inducing apoptosis successfully resulted in RAFTK (Pyk2) phosphorylation and Bim induction indicating the latter GR-mediated events were not sufficient to induce apoptosis. MM1R cells expressing mutant GRs will be helpful in defining the molecular mechanisms of dexamethasone-induced apoptosis of myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515658      PMCID: PMC2515111          DOI: 10.1182/blood-2007-11-124156

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

Authors:  D Chauhan; T Hideshima; P Pandey; S Treon; G Teoh; N Raje; S Rosen; N Krett; H Husson; S Avraham; S Kharbanda; K C Anderson
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

2.  Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.

Authors:  Beatriz Sánchez-Vega; Nancy Krett; Steven T Rosen; Varsha Gandhi
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

3.  Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors.

Authors:  T Shinjyo; R Kuribara; T Inukai; H Hosoi; T Kinoshita; A Miyajima; P J Houghton; A T Look; K Ozawa; T Inaba
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis.

Authors:  Y Tao; C Williams-Skipp; R I Scheinman
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

5.  Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim.

Authors:  P Bouillet; L C Zhang; D C Huang; G C Webb; C D Bottema; P Shore; H J Eyre; G R Sutherland; J M Adams
Journal:  Mamm Genome       Date:  2001-02       Impact factor: 2.957

6.  SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.

Authors:  D Chauhan; P Pandey; T Hideshima; S Treon; N Raje; F E Davies; Y Shima; Y T Tai; S Rosen; S Avraham; S Kharbanda; K C Anderson
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

7.  Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.

Authors:  Dharminder Chauhan; Daniel Auclair; Elisabeth K Robinson; Teru Hideshima; Guilan Li; Klaus Podar; Deepak Gupta; Paul Richardson; Robert L Schlossman; Nancy Krett; Lan Bo Chen; Nikhil C Munshi; Kenneth C Anderson
Journal:  Oncogene       Date:  2002-02-21       Impact factor: 9.867

8.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

9.  Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.

Authors:  Petra S Bachmann; Rosemary Gorman; Rachael A Papa; Jane E Bardell; Jette Ford; Ursula R Kees; Glenn M Marshall; Richard B Lock
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

10.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

View more
  24 in total

1.  Hydrogen peroxide signaling is required for glucocorticoid-induced apoptosis in lymphoma cells.

Authors:  Margaret E Tome; Melba C Jaramillo; Margaret M Briehl
Journal:  Free Radic Biol Med       Date:  2011-09-10       Impact factor: 7.376

2.  Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice.

Authors:  Stefano Bruscoli; Michele Biagioli; Daniele Sorcini; Tiziana Frammartino; Monica Cimino; Paolo Sportoletti; Emanuela Mazzon; Oxana Bereshchenko; Carlo Riccardi
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

3.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

4.  Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Authors:  Bao Hoang; Patrick Frost; Yijiang Shi; Eileen Belanger; Angelica Benavides; Gholam Pezeshkpour; Susanna Cappia; Tommasina Guglielmelli; Joseph Gera; Alan Lichtenstein
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

5.  Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Authors:  Michael A Tessel; Ashley L Benham; Nancy L Krett; Steven T Rosen; Preethi H Gunaratne
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

6.  Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.

Authors:  Carolyne Bardeleben; Sanjai Sharma; Joseph R Reeve; Sara Bassilian; Patrick Frost; Bao Hoang; Yijiang Shi; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2013-04-12       Impact factor: 6.261

7.  Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.

Authors:  Shirshendu Sinha; S Vincent Rajkumar; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Angela Dispenzieri; David Dingli; Robert A Kyle; Morie A Gertz; Shaji Kumar
Journal:  Br J Haematol       Date:  2009-12-03       Impact factor: 6.998

8.  Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.

Authors:  Patrycja M Dubielecka; Michał Grzybek; Adam Kolondra; Bozena Jaźwiec; Anna Draga; Paulina Aleksandrowicz; Monika Kołodziejczyk; Anna Serwotka; Barbara Dolińska-Krajewska; Jerzy Warchoł; Kazimierz Kuliczkowski; Aleksander F Sikorski
Journal:  Mol Cell Biochem       Date:  2010-01-08       Impact factor: 3.396

9.  Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Authors:  Kelley Salem; Charles O Brown; Jeanine Schibler; Apollina Goel
Journal:  Exp Hematol       Date:  2012-10-11       Impact factor: 3.084

10.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.